

Queensland



Drugs Misuse Act 1986

DRUGS MISUSE REGULATION 1987

**Reprinted as in force on 20 December 2002
(includes amendments up to SL No. 368 of 2002)**

Reprint No. 4C

This reprint is prepared by
the Office of the Queensland Parliamentary Counsel
Warning—This reprint is not an authorised copy

Information about this reprint

This regulation is reprinted as at 20 December 2002. The reprint shows the law as amended by all amendments that commenced on or before that day (Reprints Act 1992 s 5(c)).

The reprint includes a reference to the law by which each amendment was made—see list of legislation and list of annotations in endnotes.

This page is specific to this reprint. See previous reprints for information about earlier changes made under the Reprints Act 1992. A table of earlier reprints is included in the endnotes.

Also see endnotes for information about—

- **when provisions commenced**
- **editorial changes made in earlier reprints.**

Dates shown on reprints

Reprints dated at last amendment All reprints produced on or after 1 July 2002, hard copy and electronic, are dated as at the last date of amendment. Previously reprints were dated as at the date of publication. If a hard copy reprint is dated earlier than an electronic version published before 1 July 2002, it means the legislation was not further amended and the reprint date is the commencement of the last amendment.

If the date of a hard copy reprint is the same as the date shown for an electronic version previously published, it merely means that the electronic version was published before the hard copy version. Also, any revised edition of the previously published electronic version will have the same date as that version.

Replacement reprint date If the date of a hard copy reprint is the same as the date shown on another hard copy reprint it means that one is the replacement of the other.

Queensland



DRUGS MISUSE REGULATION 1987

TABLE OF PROVISIONS

Section		Page
PART 1—PRELIMINARY		
1	Short title	5
2	Dictionary	5
PART 2—SYRINGES AND DANGEROUS DRUGS DISPOSAL PROCEDURES		
3	Prescribed procedures for the disposal of hypodermic syringes and needles	5
4	Prescribed procedure for disposal of dangerous drugs	6
PART 3—CONTROLLED SUBSTANCES		
5	Other act that is a relevant transaction—Act, s 43C(b)	6
6	Documents and proof of identity required for supply of a controlled substance—Act, s 43D(1)(a)	7
7	Details about supply of controlled substance to be recorded in register	7
8	Details about loss or theft of controlled substance to be recorded in register	8
9	Keeping of register, invoice and other documents	9
PART 4—COMMERCIAL PRODUCTION OF INDUSTRIAL CANNABIS		
<i>Division 1—Preliminary</i>		
10	Operation of pt 4 and schs 7 and 8	9
<i>Division 2—Certified cannabis seed</i>		
11	Certifying cannabis seed	10
<i>Division 3—Carriers</i>		
12	Application of div 3	10
13	Supply	11
14	Possession	11

<i>Division 4—DPI researchers</i>		
15	Supply	11
16	Production	12
17	Possession	12
<i>Division 5—Inspectors</i>		
18	Supply	13
19	Possession	13
<i>Division 6—Seed suppliers</i>		
20	Supply	13
21	Possession	14
<i>Division 7—Other persons</i>		
22	Denaturer	14
23	Manufacturer	14
24	Analyst	14
25	Family members	15
26	Employees of authorised persons	16
<i>Division 8—Other provisions</i>		
27	Recognition as seed supplier	17
28	Licence fees	17
29	Licence conditions, Act, s 64	17
PART 5—TRANSITIONAL PROVISIONS		
30	Transitional provision for Drugs Misuse Amendment Regulation (No. 2) 2001	18
31	Transitional provision for Drugs Misuse Amendment Regulation (No. 2) 2002	18
SCHEDULE 1		
DANGEROUS DRUGS		
SCHEDULE 2		
DANGEROUS DRUGS		
SCHEDULE 2A		
DANGEROUS DRUGS		
SCHEDULE 3		

SPECIFIED QUANTITIES FOR PARTICULAR DANGEROUS DRUGS		
	SCHEDULE 4	33
SPECIFIED QUANTITIES FOR PARTICULAR DANGEROUS DRUGS		
	SCHEDULE 5	34
DANGEROUS DRUGS		
	SCHEDULE 6	37
CONTROLLED SUBSTANCES		
	SCHEDULE 7	38
CONDITIONS FOR PARTICULAR PERSONS AUTHORISED UNDER PART 4		
1	Denaturer	38
2	DPI researcher	38
3	Inspector	39
4	Seed supplier	39
5	Analyst	40
	SCHEDULE 8	42
LICENCE CONDITIONS		
	SCHEDULE 9	45
DICTIONARY		
ENDNOTES		
1	Index to endnotes	47
2	Date to which amendments incorporated	47
3	Key	47
4	Table of earlier reprints	48
5	List of legislation	48
6	List of annotations	50

DRUGS MISUSE REGULATION 1987

[as amended by all amendments that commenced on or before 20 December 2002]

PART 1—PRELIMINARY

1 Short title

This regulation may be cited as the *Drugs Misuse Regulation 1987*.

2 Dictionary

The dictionary in schedule 9 defines particular words used in this regulation.

PART 2—SYRINGES AND DANGEROUS DRUGS DISPOSAL PROCEDURES

3 Prescribed procedures for the disposal of hypodermic syringes and needles

For the purposes of section 10(4A) of the Act, the prescribed procedures for the disposal of a hypodermic syringe or needle shall be as follows—

- (a) by placing the hypodermic syringe or needle in a rigid wall, puncture resistant container and that container is sealed or securely closed in such a manner that its contents are incapable of causing injury to any person; or
- (b) by giving the hypodermic syringe or needle to a person who is a medical practitioner, pharmacist or person or a member of a class of persons referred to as authorised in section 10(3) of the Act.

4 Prescribed procedure for disposal of dangerous drugs

For the purposes of section 52A¹ of the Act, the prescribed procedure for the disposal of a thing shall be as follows—

- (a) in the case where the thing is a trace amount of a dangerous drug contained in a hypodermic syringe or needle, by disposing of the hypodermic syringe or needle in accordance with the procedures prescribed in section 9; or
- (b) in any other case, at the first reasonable opportunity, by giving—
 - (i) such thing; and
 - (ii) where such thing is contained in a hypodermic syringe or needle, such syringe or needle;

to an officer authorised to exercise the powers contained in the *Health Act 1937*, section 132.²

PART 3—CONTROLLED SUBSTANCES

5 Other act that is a relevant transaction—Act, s 43C(b)

Any act by which a controlled substance is supplied³ by a person, in or in connection with the person's business, to anyone else is a relevant transaction for the supply of a controlled substance.

Example—

A and B are partners in a chain of pharmacies. They make cold tablets to sell in the pharmacies by compounding ephedrine (a controlled substance) with other substances.

The partners sell some of the left over ephedrine to a pharmaceutical research company and give the rest away.

Both the sale and gift of ephedrine are relevant transactions.

1 Section 52A (Prescribed persons permitted to receive and dispose of dangerous drugs) of the Act was renumbered as section 125—now see *Drugs Misuse Act Amendment Act 2002*, section 11.

2 Now see part 4A (Monitoring, investigation and enforcement), division 3 (Powers of inspectors) of the *Health Act 1937*.

3 Under section 43A of the Act, “supply” means give, distribute, sell or supply.

6 Documents and proof of identity required for supply of a controlled substance—Act, s 43D(1)(a)

(1) This section applies to a person who supplies a controlled substance under a relevant transaction to anyone else (a “**recipient**”).

(2) The person must, before supplying the substance, obtain from the recipient a written order for the supply of the substance showing the following information—

- (a) the recipient’s name and address, and if the recipient purports to obtain the substance for another person, the other person’s name and address;
- (b) the date and number of the order;
- (c) the name and quantity of the substance to be supplied;
- (d) the purpose for which the substance is to be supplied.

(3) If the recipient is an individual, the person must, before supplying the substance, require the recipient to produce an official document containing the recipient’s photograph (for example, a passport or drivers licence) as evidence of the recipient’s identity.

(4) The person must, immediately the person supplies the substance under the transaction, make an invoice for the supply of the substance showing the following details—

- (a) the recipient’s name and address;
- (b) the recipient’s order number for the supply of the substance;
- (c) the date the substance was supplied;
- (d) the name and quantity of the substance supplied.

Maximum penalty for subsection (4)—20 penalty units.

7 Details about supply of controlled substance to be recorded in register

(1) The following details about a relevant transaction for the supply of a controlled substance must be recorded in the register⁴—

4 See section 43D(1)(c) of the Act for the requirement to keep the register.

- (a) the name and address of the recipient and, if the recipient purports to obtain the substance for another person, the other person's name and address;
- (b) the recipient's order number for the supply of the substance;
- (c) the invoice number for the supply of the substance;
- (d) if the recipient is—
 - (i) a company—its Australian Company Number; or
 - (ii) an individual—the type of official document produced under section 12(3) and the following details about the document—
 - (A) who issued it;
 - (B) its serial number or other identifying number or mark;
- (e) the name and quantity of the substance supplied;
- (f) the date the substance was supplied;
- (g) the purpose for which the substance was supplied.

(2) The details must be recorded in the register as soon as practicable, but in no case later than 7 days, after the day the person supplied the substance under the transaction.

(3) Nothing in this section prevents the keeping of a single register for the Act and another Act if—

- (a) the keeping of the single register is not contrary to the other Act; and
- (b) the details recorded under subsection (1) are easily identifiable in the single register.

8 Details about loss or theft of controlled substance to be recorded in register

The following details of the reporting to a police officer of the loss or theft of a controlled substance must be recorded in the register—

- (a) the day and place the report was made;
- (b) the name and registered number of the officer to whom the report was made;
- (c) the name and quantity of the substance lost or stolen.

9 Keeping of register, invoice and other documents

(1) This section applies to the register and other documents mentioned in the Act, section 43D(1)⁵ and the invoice required under section 12(4).

(2) A person who supplies a controlled substance under a relevant transaction must keep the register, documents or invoice—

- (a) at the principal or only place in Queensland where the person engages in relevant transactions; and
- (b) for 2 years from the day the person supplied the substance under the transaction.

PART 4—COMMERCIAL PRODUCTION OF INDUSTRIAL CANNABIS*Division 1—Preliminary***10 Operation of pt 4 and schs 7 and 8**

(1) Divisions 3 to 7 state activities stated persons are authorised to perform for the purposes of part 5B of the Act.

(2) Schedule 7 states conditions applying to particular persons who perform activities stated in divisions 4, 5, 6 and 7.

(3) If a word used in this part, schedule 7 or schedule 8 is not defined in the dictionary but is defined for part 5B of the Act, the word has the same meaning as in that part, unless a contrary intention appears.⁶

5 Section 43D (Requirements for supply of controlled substance under relevant transactions) of the Act

6 *Drugs Misuse Act 1986*, part 5B (Commercial production of industrial cannabis) and section 46 (Definitions for pt 5B).

*Division 2—Certified cannabis seed***11 Certifying cannabis seed**

(1) The way seed originating in Queensland is to be certified for the definition “**certified cannabis seed**” in section 46 of the Act is stated in the Industrial Cannabis THC Seed Certification Code of Practice approved by the chief executive by gazette notice.⁷

(2) The way cannabis seed originating in another State or a foreign country (“**imported seed**”) is certified for the definition “**certified cannabis seed**” in section 46 of the Act is stated in subsection (3).

(3) The seed must be in a package that—

- (a) has a document attached to it certifying that the seed—
 - (i) has been certified in accordance with a recognised quality assurance program; and
 - (ii) if grown, will produce cannabis plants with a THC concentration in their leaves and flowering heads of not more than 0.5%; and
- (b) describes the contents of the package as seed that, if grown, will produce cannabis plants with a THC concentration in their leaves and flowering heads of not more than 0.5%.

*Division 3—Carriers***12 Application of div 3**

This division applies to a carrier only if the carrier is engaged or employed by any of the following to transport consigned cannabis—

- (a) a category 1 or category 2 researcher;
- (b) a grower;
- (c) a DPI researcher;

⁷ The code is a departmental document and is published by the department. A copy of the code may be obtained or inspected without charge from the department’s head office at 80 Ann Street, Brisbane during normal business hours. The department’s internet site is at www.dpi.qld.gov.au and the code is also available there.

- (d) an inspector;
- (e) a seed supplier.

13 Supply

(1) The carrier is authorised to transport consigned cannabis and give it to the person to whom it is consigned.

(2) The authorisation—

- (a) is for the time necessary for the carrier to transport the consigned cannabis and give it to the person to whom it is consigned; and
- (b) has effect only while the carrier is acting in accordance with the terms of the carrier's engagement or employment.

14 Possession

(1) The carrier is authorised to possess consigned cannabis for the time necessary for the carrier to transport it to the person to whom it is consigned and give it to the person.

(2) The authorisation has effect only while the carrier is acting in accordance with the terms of the carrier's engagement or employment.

Division 4—DPI researchers

15 Supply

A DPI researcher is authorised—

- (a) to supply class A research cannabis plants and seed to another DPI researcher or a category 1 researcher; and
- (b) to supply class B research cannabis plants and seed to another DPI researcher or a category 1 or category 2 researcher; and
- (c) to supply class A and class B research cannabis seed to a grower for use, under the DPI researcher's supervision, as part of a field trial the DPI researcher is conducting on land owned or leased by the grower; and
- (d) to supply industrial cannabis seed to any of the following—
 - (i) a grower;

- (ii) a category 1 or category 2 researcher;
 - (iii) another DPI researcher;
 - (iv) the owner or operator of a facility at which industrial cannabis seed may be denatured;
 - (v) the owner or operator of a facility where processed cannabis is, or is to be, used for manufacturing a manufactured product for sale by wholesale or retail; and
- (e) to supply class A or class B research cannabis seed or industrial cannabis seed to a person in another State who is authorised under the law of that State to possess cannabis seed that, if grown, will produce plants with a THC concentration in their leaves and flowering heads that the person in the other State may possess; and
 - (f) to supply class A or class B research cannabis plants, industrial cannabis plants or processed cannabis to an analyst; and
 - (g) to supply processed cannabis to the owner or operator of a facility where processed cannabis is used for manufacturing a manufactured product for sale by wholesale or retail.

16 Production

A DPI researcher is authorised to produce, for use in plant breeding programs for developing new commercial strains of industrial cannabis—

- (a) industrial cannabis plants and seed; and
- (b) class A and class B research cannabis plants and seed.

17 Possession

A DPI researcher is authorised to possess any of the following for a purpose mentioned in section 15 or 16—

- (a) industrial cannabis plants and seed;
- (b) class A and class B research cannabis plants and seed;
- (c) processed cannabis.

Division 5—Inspectors**18 Supply**

An inspector is authorised —

- (a) to supply industrial cannabis plants, class A or class B research cannabis plants or processed cannabis to an analyst to analyse the THC concentration in any of them; and
- (b) if the inspector is given industrial cannabis plants or seed or class A or class B research cannabis plants or seed for delivery to a particular person who is lawfully entitled to possess the plants or seed—to supply the plants or seed to the person.

19 Possession

An inspector is authorised—

- (a) to possess industrial cannabis plants, class A or class B research cannabis plants or processed cannabis given to the inspector for delivery to an analyst to analyse the THC concentration in the plants or processed cannabis; and
- (b) to possess industrial cannabis plants or seed or class A or class B research cannabis plants or seed given to the inspector for delivery to a person lawfully entitled to possess the plants or seed.

Division 6—Seed suppliers**20 Supply**

A seed supplier is authorised to supply industrial cannabis seed to any of the following—

- (a) a category 1 or category 2 researcher;
- (b) a grower;
- (c) a DPI researcher;
- (d) a person in another State who is authorised under the law of that State to possess cannabis seed that, if grown, will produce

cannabis plants with a THC concentration in their leaves and flowering heads the person in the other State may possess;

- (e) if the seed supplier holds a licence under the *Customs Act 1901* (Cwlth) authorising the seed supplier to export cannabis—a person in a foreign country who is authorised under the law of the country to possess the seed.

21 Possession

A seed supplier is authorised to possess industrial cannabis seed for the purpose of supplying it to a person mentioned in section 20.

Division 7—Other persons

22 Denaturer

(1) The owner or operator of a facility where industrial cannabis seed may be denatured under an agreement or arrangement with a licensee or another person authorised under this part to produce industrial cannabis seed (“**denaturer**”), is authorised to possess industrial cannabis seed supplied to the owner or operator, but only for the purpose of denaturing the seed.

(2) A denaturer is authorised to supply denatured seed to a person who is authorised to possess processed cannabis.

23 Manufacturer

The owner or operator of a facility where processed cannabis is used for manufacturing a manufactured product for sale by wholesale or retail is authorised to possess processed cannabis for using it for manufacturing a manufactured product.

24 Analyst

(1) An analyst is authorised to possess—

- (a) standard THC material to calibrate an analytical instrument used for analysing a substance to determine its THC concentration; and

- (b) if an authorised person engages or employs the analyst to analyse a substance to determine its THC concentration—the substance for the purpose of the analysis.

(2) In this section—

“authorised person” means any of the following—

- (a) a category 1 or category 2 researcher;
- (b) a grower;
- (c) a DPI researcher;
- (d) an inspector.

“substance” means a substance that an authorised person reasonably believes to be any of the following—

- (a) industrial cannabis plants;
- (b) class A or class B research cannabis plants;
- (c) processed cannabis.

25 Family members

(1) A person who is a member of the immediate family of a licensee is authorised to produce, possess or supply a substance if—

- (a) the licensee is authorised to produce, possess or supply the substance under the Act; and
- (b) the person’s production, possession or supply of the substance is necessary for, or incidental to the licensee’s production, possession or supply of the substance.

(2) In this section —

“substance” means any of the following—

- (a) class A research cannabis plants;
- (b) class A research cannabis seed;
- (c) class B research cannabis plants;
- (d) class B research cannabis seed;
- (e) industrial cannabis plants;

- (f) industrial cannabis seed;
- (g) processed cannabis.

26 Employees of authorised persons

(1) An employee of an authorised person is authorised to produce, possess, supply or transport a substance if—

- (a) under the Act, the authorised person is authorised to produce, possess, supply or transport the substance; and
- (b) the employee's production, possession, supply or transportation of the substance is necessary for, or incidental to, performing the employee's employment or engagement.

(2) In this section—

“authorised person” means any of the following—

- (a) a licensee;
- (b) a carrier;
- (c) a DPI researcher;
- (d) an inspector;
- (e) a seed supplier;
- (f) a denaturer;
- (g) a manufacturer;
- (h) an analyst.

“employee” includes agent.

“substance” means any of the following—

- (a) class A research cannabis plant;
- (b) class A research cannabis seed;
- (c) class B research cannabis plant;
- (d) class B research cannabis seed;
- (e) industrial cannabis plant;
- (f) industrial cannabis seed;
- (g) processed cannabis.

Division 8—Other provisions**27 Recognition as seed supplier**

(1) A person may apply in writing to the chief executive for recognition as a seed supplier.

(2) The chief executive must recognise the person as a seed supplier if the chief executive is satisfied the person—

- (a) for trade or commerce, sells or otherwise provides seeds to someone else; and
- (b) for selling or providing the seed, has a current recognised quality assurance program that conforms to an industry standard or code of practice; and
- (c) is a member of the Queensland Seed Industry Association or a similar organisation in another State.

(3) The chief executive must give a person recognised as a seed supplier written notice of the recognition.

(4) The recognition notice must state—

- (a) the person's recognition number as a seed supplier; and
- (b) the date the recognition ends, which must not be longer than 3 years after the date of the notice.

(5) The recognition is not transferable.

28 Licence fees

(1) The fee payable on application for a licence under the Act, part 5B is \$300.

(2) The fee payable on application for the renewal of a licence is \$120.

29 Licence conditions, Act, s 64

(1) The conditions in schedule 8 are prescribed for section 64(3)⁸ of the Act.

8 Section 64 (Term and conditions) of the Act

(2) Unless otherwise expressly stated, the conditions apply to all licensees.

PART 5—TRANSITIONAL PROVISIONS

30 Transitional provision for Drugs Misuse Amendment Regulation (No. 2) 2001

(1) To remove doubt, it is declared that this regulation, as in force immediately before the commencement of the *Drugs Misuse Amendment Regulation (No. 2) 2001* (the “**amending regulation**”), continues to apply in relation to an offence against the Act committed before the commencement of the amending regulation.

(2) Proceedings for an offence against the Act committed before the commencement of the amending regulation may be continued or started as if the amending regulation had not been made.

31 Transitional provision for Drugs Misuse Amendment Regulation (No. 2) 2002

(1) To remove doubt, it is declared that this regulation, as in force immediately before the commencement of this section, continues to apply in relation to an offence against the Act committed before the commencement of this section.

(2) Proceedings for an offence against the Act committed before the commencement of this section may be continued or started as if the *Drugs Misuse Amendment Regulation (No. 2) 2002* had not been made.

SCHEDULE 1

DANGEROUS DRUGS

sections 4, 5, 6, 8, 8A, 9 and 134 of the Act

Amphetamine

Cocaine

Heroin

Lysergide

Methylamphetamine

Phencyclidine

SCHEDULE 2**DANGEROUS DRUGS**

sections 4, 5, 6, 8, 8A, 9 and 134 of the Act

Acetorphine

Acetyldihydrocodeine, except where it is compounded with 1 or more other medicaments in such a way that it cannot be readily extracted and where it is contained—

- (a) in divided preparations containing 100 mg or less of acetyldihydrocodeine per dosage unit; or
- (b) in undivided preparations containing 2.5% or less of acetyldihydrocodeine

Acetylmethadol

Acetylmorphines

Alfentanil

Alkoxyamphetamines and bromo-substituted alkoxyamphetamines except where separately specified

Alkoxyphenethylamines and alkyl-substituted alkoxyphenethylamines except where separately specified

Allylprodine

Alphacetylmethadol

Alphameprodine

Alphamethadol

Alphaprodine

Anileridine

Barbituric acid and any 5,5 disubstituted derivatives of barbituric acid, whether or not further substituted at position 1 of the ring

Benzethidine

Benzylmorphine

SCHEDULE 2 (continued)

Betacetylmethadol

Betameprodine

Betamethadol

Betaprodine

Bezitramide

4-Bromo-2,5-dimethoxyamphetamine

4-Bromo-2,5-dimethoxyphenethylamine

Bufotenine

Buprenorphine

Cannabinoids except tetrahydrocannabinols

Cannabis sativa

Clonitazene

Coca leaf

Codeine, except where it is compounded with 1 or more other medicaments in such a way that it cannot be readily extracted and where it is contained—

- (a) in divided preparations containing 30 mg or less of codeine per dosage unit; or
- (b) in undivided preparations containing 1% or less of codeine

Codeine-N-oxide

Codoxime

4-Cyano-1-Methyl-4-Phenylpiperidine

4-Cyano-2-Dimethylamino-4,4-Diphenylbutane

Desomorphine

Diampromide

Diethylthiambutene

N,N-Diethyltryptamine

SCHEDULE 2 (continued)

Difenoxin except in preparations containing 0.5 mg or less of difenoxin and a quantity of atropine sulphate equivalent to not less than 5% of the dose of difenoxin per dosage unit

Dihydrocodeine except where it is compounded with 1 or more other medicaments in such a way that it cannot be readily extracted and where it is contained—

(a) in divided preparations containing 100 mg or less of dihydrocodeine per dosage unit; or

(b) in undivided preparations containing 2.5% or less of dihydrocodeine

Dihydromorphine

Dimenoxadol

Dimepheptanol

2,5-Dimethoxyamphetamine

2,5-Dimethoxy-4-Ethylamphetamine (DOET)

2,5-Dimethoxy-4-Methylamphetamine

Dimethylamino-1,2-Diphenylethane

3-(1,2-Dimethylheptyl)-1-Hydroxy-7,8,9,10-Tetrahydro-6,6,9-Trimethyl-6-H-Dibenzo(b,d)Pyran

Dimethylthiambutene

N,N-Dimethyltryptamine

Dioxaphetyl butyrate

Diphenoxylate except in preparations containing 2.5 mg or less of diphenoxylate and a quantity of atropine sulphate equivalent to not less than 1% of the dose of diphenoxylate per dosage unit

Dipipanone

Drotebanol

Ecgonine, its esters and derivatives which are convertible to ecgonine and cocaine

Ethylmethylthiambutene

SCHEDULE 2 (continued)

Ethylmorphine except where it is compounded with 1 or more other medicaments in such a way that it cannot be readily extracted and where it is contained—

- (a) in divided preparations containing 100 mg or less of ethylmorphine per dosage unit; or
- (b) in undivided preparations containing 2.5% or less of ethylmorphine

N-Ethyl-1-Phencyclohexylamine

Etonitazine

Etorphine

Etoxadine

Fenethylamine

Fentanyl

Furethidine

Gamma hydroxybutyric acid

Hydrocodone

Hydromorphanol

Hydromorphone

Hydroxypethidine

4-Iodo-2,5-dimethoxyphenethylamine (2C-I)

Isomethadone

Ketamine

Ketobemidone

Levophenacetylmorphan

Lysergamide and N-alkyl derivatives of lysergamide other than lysergide

Lysergic acid

Mecloqualone

Mescaline (3,4,5-Trimethoxyphenethylamine)

Metazocine

SCHEDULE 2 (continued)

Methadone

Methaqualone

Methcathinone

5-Methoxy-3,4-Methylenedioxyamphetamine (MMDA)

2-Methylamino-1-(3,4-methylenedioxyphenyl) butane (MBDB)

4-Methylaminorex

Methyldesorphine

Methyldihydromorphine

3,4-Methylenedioxyamphetamine

3,4-Methylenedioxyethylamphetamine (MDEA)

3,4-Methylenedioxymethamphetamine (MDMA)

2-Methyl-3-Morpholino-1, 1-Diphenylpropane Carboxylic acid

Methylphenidate

4-Methylthioamphetamine (4-MTA)

1-Methyl-4-Phenylpiperidine-4-Carboxylic acid

Metopon

Moramide

Morpheridine

Morphine

Morphine methobromide

Morphine-N-oxide

Myrophine

Nabilone

N-Benzylpiperazine (BZP)

Nicocodine, except where it is compounded with 1 or more other medicaments in such a way that it cannot be readily extracted and where it is contained—

- (a) in divided preparations containing 100 mg or less of nicocodine per dosage unit; or

SCHEDULE 2 (continued)

(b) in undivided preparations containing 2.5% or less of nicocodine Nicodicodine, except where it is compounded with 1 or more other medicaments in such a way that it cannot be readily extracted and where it is contained—

(a) in divided preparations containing 100 mg or less of nicodicodine per dosage unit; or

(b) in undivided preparations containing 2.5% or less of nicodicodine

Nicomorphine

Noracymethadol

Norcodeine, except where it is compounded with 1 or more other medicaments in such a way that it cannot be readily extracted and where it is contained—

(a) in divided preparations containing 100 mg or less of norcodeine per dosage unit; or

(b) in undivided preparations containing 2.5% or less of norcodeine

Norlevorphanol

Normethadone

Normorphine

Norpipanone

Opium

Oxycodone

Oxymorphone

Papaver orientale

Papaver setigerum

Papaver somniferum L. except the seed thereof which seed has been rendered sterile

Parahexyl

Paramethoxyamphetamine (PMA)

Pentazocine

SCHEDULE 2 (continued)

Pethidine

Phenadoxone

Phenampramide

Phenazocine

Phendimetrazine

Phenmetrazine

Phenomorphane

Phenoperidine

1-(1-Phenylcyclohexyl)pyrrolidine

4-Phenylpiperidine-4-Carboxylic acid ethyl ester

Pholcodine, except where it is compounded with 1 or more other medicaments in such a way that it cannot be readily extracted and where it is contained—

(a) in divided preparations containing 100 mg or less of pholcodine per dosage unit; or

(b) in undivided preparations containing 2.5% or less of pholcodine

Piminodine

Piritramide

Proheptazine

Propiridine

Propiram

Psilocin

Psilocybin

Racemethorphan

Racemoramide

Racemorphan

Salvia Divinorum

Sufentanil

SCHEDULE 2 (continued)

Tetrahydrocannabinols including their alkyl homologues except where separately specified; and their corresponding carboxylic acids

Thebacon

Thebaine

1-(1-(2-thienyl)cyclohexyl)piperidine

Tilidine

1-(3-Trifluoromethylphenyl) piperazine (TFMPP)

Trimeperidine

3, 4, 5-Trimethoxyamphetamine (TMA)

SCHEDULE 2A**DANGEROUS DRUGS**

sections 4, 5, 6, 8, 8A, 9 and 134 of the Act

Androisoxazole

Atamestane

Bambuterol

Bolandiol

Bolasterone

Bolazine

Boldenone (dehydrotestosterone)

Bolenol

Bolmantalate

Calusterone

Chlorandrostenolone

4-Chloromethandienone

Chloroxydienone

Chloroxymesterone (dehydrochloromethyltestosterone)

Clenbuterol

Clostebol (4-chlorotestosterone)

Danazol

Dihydrolone

Dimethandrostanolone

Drostanolone

Enestebol

Ephedrine

Epitiostanol

SCHEDULE 2A (continued)

Ethyldienolone

Ethylestrenol

Fenoterol

Flunitrazepam

Fluoxymesterone

Formebolone (formyldienolone)

Formoterol

Furazabol

Hydroxystenozol

Mebolazine

Mepitiostane

Mesabolone

Mestanolone (androstalone)

Mesterolone

Methandienone

Methandriol

Methenolone

Methylclostebol

Methyltestosterone

Methyltrienolone

Metribolone

Mibolerone

Nandrolone

Norandrostenolone

Norbolethone

Norclostebol

Norethandrolone

Normethandrone

SCHEDULE 2A (continued)

Ovandrotone

Oxabolone

Oxandrolone

Oxymesterone

Oxymethalone

Prasterone

Propetandrol

Quinbolone

Reproterol

Salbutamol, except in metered aerosols or dry powder or capsules of dry powder for inhalation

Silandrone

Somatotropin

Stanolone

Stanzolol

Stenbolone

Terbutaline, except in metered aerosols for inhalation

Testolactone

Testosterone, except in implant preparations for growth promotion in animals

Thiomesterone (tiomesterone)

Trenbolone (trienbolone, trienolone), except in implant preparations for use in animals

Trestolone

Any other anabolic and androgenic steroidal agent

SCHEDULE 3**SPECIFIED QUANTITIES FOR PARTICULAR
DANGEROUS DRUGS**

sections 4, 8, 9, 125 and 134 of the Act

Dangerous drug	Quantity of dangerous drug
Amphetamine	2.0 g
Barbituric Acid and any 5,5 disubstituted derivatives of barbituric acid whether or not further substituted at position 1 of the ring	50.0g
4-Bromo-2,5-dimethoxyamphetamine	0.5g
4-Bromo-2,5-dimethoxyphenethylamine	2.0 g
Cannibis sativa	500.0 g or, if the dangerous drug consists of plants the aggregate weight of which is less than 500.0 g, 100 plants
Cocaine	2.0 g
Codeine	10.0 g
N,N-Diethyltryptamine	2.0g
2,5-Dimethoxy-4-Ethylamphetamine (DOET)	2.0 g
2,5-Dimethoxy-4-Methylamphetamine	2.0 g
N,N-Dimethyltryptamine	2.0 g
Fenethylline	2.0 g
Fentanyl	0.01 g
Gamma hydroxybutyric acid	2.0 g
Heroin	2.0 g
Hydromorphone	2.0 g

SCHEDULE 3 (continued)

Dangerous drug	Quantity of dangerous drug
Lysergide	0.004 g
Methadone	2.0 g
Methcathinone	2.0 g
5-Methoxy-3,4-Methylenedioxyamphetamine (MMDA)	2.0 g
2-Methylamino-1-(3,4-methylenedioxyphenyl) butane (MBDB)	2.0g
4-Methylaminorex	2.0 g
Methylamphetamine	2.0 g
3,4-Methylenedioxyethylamphetamine (MDEA)	2.0 g
3,4-Methylenedioxymethamphetamine (MDMA)	2.0 g
4-Methylthioamphetamine (4-MTA)	2.0 g
Moramide	2.0 g
Morphine	2.0 g
Opium	20.0 g
Paramethoxyamphetamine (PMA)	2.0 g
Pethidine	10.0 g
Phencyclidine	0.5 g
Psilocin	0.10 g
Psilocybin	0.10 g
Tetrahydrocannabinols including their alkyl homologues except where separately specified; and their corresponding carboxylic acids	2.0 g
3,4,5-Trimethoxyamphetamine (TMA)	2.0 g

SCHEDULE 4**SPECIFIED QUANTITIES FOR PARTICULAR
DANGEROUS DRUGS**

sections 4, 8, 9 and 134 of the Act

Dangerous drug	Quantity of dangerous drug
Amphetamine	200.0 g
Cocaine	200.0 g
Heroin	200.0 g
Lysergide	0.4 g
Methylamphetamine	200.0 g
Phencyclidine	50.0 g

SCHEDULE 5**DANGEROUS DRUGS**

sections 4, 124 and 134 of the Act

Barbituric acid and any 5,5 disubstituted derivatives of barbituric acid, whether or not further substituted at position 1 of the ring

Buprenorphine

Codeine, except where it is compounded with 1 or more other medicaments in such a way that it cannot be readily extracted and where it is contained—

- (a) in divided preparations containing 30 mg or less of codeine per dosage unit; or
- (b) in undivided preparations containing 1% or less of codeine

Difenoxin except in preparations containing 0.5 mg or less of difenoxin and a quantity of atropine sulphate equivalent to not less than 5% of the dose of difenoxin per dosage unit

Dihydrocodeine, except where it is compounded with 1 or more other medicaments in such a way that it cannot be readily extracted and where it is contained—

- (a) in divided preparations containing 100 mg or less of dihydrocodeine per dosage unit; or
- (b) in undivided preparations containing 2.5% or less of dihydrocodeine

Diphenoxylate except in preparations containing 2.5 mg or less of diphenoxylate and a quantity of atropine sulphate equivalent to not less than 1% of the dose of diphenoxylate per dosage unit

Ethylmorphine, except where it is compounded with 1 or more other medicaments in such a way that it cannot be readily extracted and where it is contained—

- (a) in divided preparations containing 100 mg or less of ethylmorphine per dosage unit; or

SCHEDULE 5 (continued)

- (b) in undivided preparations containing 2.5% or less of ethylmorphine

Hydrocodone

Hydromorphone

Ketamine

Methadone

Methylphenidate

Moramide

Morphine

Nicocodine, except where it is compounded with 1 or more other medicaments in such a way that it cannot be readily extracted and where it is contained—

- (a) in divided preparations containing 100 mg or less of nicocodine per dosage unit; or
- (b) in undivided preparations containing 2.5% or less of nicocodine

Nicodicodine, except where it is compounded with 1 or more other medicaments in such a way that it cannot be readily extracted and where it is contained—

- (a) in divided preparations containing 100 mg or less of nicodicodine per dosage unit; or
- (b) in undivided preparations containing 2.5% or less of nicodicodine

Norcodeine, except where it is compounded with 1 or more other medicaments in such a way that it cannot be readily extracted and where it is contained—

- (a) in divided preparations containing 100 mg or less of norcodeine per dosage unit; or
- (b) in undivided preparations containing 2.5% or less of norcodeine

Normethadone

Oxycodone

Pentazocine

SCHEDULE 5 (continued)

Pethidine

Phenazocine

Phendimetrazine

Phenmetrazine

Pholcodine except where it is compounded with 1 or more other medicaments in such a way that it cannot be readily extracted and where it is contained—

- (a) in divided preparations containing 100 mg or less of pholcodine per dosage unit; or
- (b) in undivided preparations containing 2.5% or less of pholcodine

Racemethorphan

Racemoramide

Racemorphan

SCHEDULE 6**CONTROLLED SUBSTANCES**

sections 43A and 134 of the Act

1-Chloro-Phenyl-2-Aminopropane

1-Phenyl-2-Chloropropane

1-Phenyl-2-Methylaminopropane

1-Phenyl-2-Nitro propene

Acetic Anhydride

Benzyl Cyanide

Boron Tribromide

Ephedrine

Hydriodic Acid

Hypophosphorous acid

Phenyl Acetic Acid

Phenylpropanolamine

Phenyl-2-Propanone

Phenyl-2-Propanone Oxime

Pseudoephedrine

Pyridine

Red phosphorous

SCHEDULE 7**CONDITIONS FOR PARTICULAR PERSONS
AUTHORISED UNDER PART 4**

section 10(2)

1 Denaturer

A denaturer must—

- (a) keep industrial cannabis seed that has not been denatured in a securely locked place, other than when removing it to enable it to be denatured; and
- (b) keep records of—
 - (i) the source and quantity of all industrial cannabis seed received for denaturing; and
 - (ii) when and by whom the industrial cannabis seed was delivered to the denaturer; and
- (c) must pay the chief executive's reasonable costs of monitoring the denaturer's activities to the extent to which they relate to the denaturing of industrial cannabis seed and the supply of processed cannabis to a manufacturer.

2 DPI researcher

A DPI researcher must—

- (a) keep class A research cannabis plants the researcher is growing securely locked in a glasshouse; and
- (b) grow class B research cannabis plants in an area that is fenced to delineate the area under production; and
- (c) if the chief executive requires the researcher to erect signs indicating the presence of class B research cannabis at a fenced area, ensure the signs are erected as required by the chief executive; and

SCHEDULE 7 (continued)

- (d) keep industrial cannabis seed and class A and class B research cannabis seed in the researcher's possession or under the researcher's control locked in a secure place when not otherwise required—
 - (i) for use for planting; or
 - (ii) to be supplied to another person; and
- (e) keep a register that includes the following information—
 - (i) the varieties or strains of cannabis plants and cannabis seed under the researcher's control;
 - (ii) the source, quantity and delivery details for cannabis seed and plant varieties the researcher receives;
 - (iii) how, when and from whom the researcher received cannabis plants and seed delivered to the researcher;
 - (iv) if a carrier delivered the cannabis plants or seed to the researcher, the name of the person who delivered the plants or seed;
 - (v) if a researcher engages a carrier to deliver cannabis plants or seed to someone else—
 - (A) the name of the person to whom the plants or seed were given for delivery; and
 - (B) the name of the person to whom it is intended the plants or seed be supplied by the researcher.

3 Inspector

An inspector who possesses industrial cannabis plants or seed or class A or class B research cannabis plants or seed for supplying them to someone else under part 4 must keep the plants or seed in a secure place until the inspector supplies them to the person.

4 Seed supplier

A seed supplier must—

- (a) keep industrial cannabis seed in the supplier's possession or under the supplier's control locked in a secure place when not

SCHEDULE 7 (continued)

otherwise required for use for lawfully supplying the seed to a person mentioned in section 20; and

- (b) keep records of the following information—
 - (i) the source and quantity of all industrial cannabis seed supplied to the supplier;
 - (ii) how, when and by whom industrial cannabis seed was delivered to the supplier;
 - (iii) if industrial cannabis seed is delivered to the supplier by a carrier—the name of the person who actually delivered the seed;
 - (iv) if the supplier supplies industrial cannabis seed to a carrier for delivery to a person—
 - (A) the name of the person to whom the seed was given for delivery; and
 - (B) the name of the person to whom it is intended the seed be supplied by the supplier;
 - (v) the name of each person to whom the supplier supplies industrial cannabis seed; and
- (c) ensure all industrial cannabis seed received by the seed supplier is labelled to indicate—
 - (i) if the seed is cannabis seed harvested from an industrial cannabis plant—that fact; or
 - (ii) if the seed is certified cannabis seed—that fact; and
- (d) ensure that each package of certified cannabis seed supplied by the seed supplier has a label on it, or attached to it, that describes the contents of the package as certified cannabis seed; and
- (e) pack all industrial cannabis seed to be delivered to someone else by a carrier in a way that ensures, as far as reasonably practicable, seed can not be lost if the package is damaged.

5 Analyst

(1) This section applies if an analyst is engaged or employed to analyse a substance to determine its THC concentration.

SCHEDULE 7 (continued)

(2) The analyst must analyse the substance in a laboratory whose functions and operations are accredited by NATA for competence to undertake drug analysis.

(3) The analyst must keep standard THC material in a securely locked place other than when the analyst is using the material in analysing the substance to determine its THC concentration.

(4) The analyst must keep the substance in a securely locked place other than when the analyst is analysing the substance.

(5) In this section—

“**NATA**” means the National Association of Testing Authorities, Australia
ABN 59 004 379 748.

“**substance**” means a substance the analyst reasonably believes to be any of the following—

- (a) industrial cannabis plants;
- (b) class A or class B research cannabis plants;
- (c) processed cannabis.

SCHEDULE 8**LICENCE CONDITIONS**

section 29(1)

1. A licensee who is authorised to produce class A research cannabis must—
 - (a) grow the cannabis in a glasshouse that is capable of being securely locked; and
 - (b) keep the glasshouse securely locked other than when the licensee or a person authorised by the licensee is performing functions directly associated with growing cannabis in the glasshouse.
2. A licensee who is authorised to produce class B research cannabis must—
 - (a) grow the cannabis in an area that is fenced to delineate the area under production; and
 - (b) if the chief executive requires the licensee to erect signs indicating the presence of class B research cannabis at a fenced area, ensure the signs are erected as required by the chief executive.
3. A licensee must keep cannabis seed in the licensee's possession in a securely locked place, other than when the licensee uses the seed for a purpose that is authorised under the licensee's licence.
4. A licensee must keep a register of the following—
 - (a) the strains or varieties of cannabis seed in the licensee's possession;
 - (b) the strains or varieties of cannabis plants the licensee is growing.
5. A licensee must keep records of the following information—
 - (a) the source and quantity of all cannabis plants and seed supplied to the licensee;
 - (b) how, when and by whom plants or seed were delivered to the licensee;

SCHEDULE 8 (continued)

- (c) if cannabis plants or seed are delivered to the licensee by a carrier—the name of the person who actually delivered the plants or seed;
- (d) if cannabis plants or seed are supplied to a carrier for delivery to a person—
 - (i) the name of the person to whom the plants or seed were given for delivery; and
 - (ii) the name of the person to whom it is intended the plants or seed be supplied by the carrier.
- 6. As soon as reasonably practicable after a licensee receives a package containing cannabis plants or seed that appears to have been tampered with, the licensee must inform an inspector or a police officer that the package appears to have been tampered with.
- 7. A licensee must pay the chief executive's reasonable costs of monitoring activities performed under the licence, including any costs of an analyst conducting a laboratory analysis necessary to determine the concentration of THC in the leaves and flowering heads of cannabis plants in the licensee's possession.
- 8. A category 2 researcher must allow an inspector to destroy, or supervise the destruction of, cannabis plants in the possession of the licensee that have been found, by an analyst conducting a laboratory analysis of a random sample of the leaves and flowering heads of the plants, to have a concentration of THC in their leaves and flowering heads of 3% or more.
- 9. A grower must allow an inspector to destroy, or supervise the destruction of, cannabis plants in the possession of the licensee that have been found, by an analyst conducting a laboratory analysis of a random sample of the leaves and flowering heads of the plants, to have a THC concentration in their leaves and flowering heads of more than 1%.
- 10. A licensee who proposes to supply industrial cannabis seed for sale by wholesale or retail must ensure—
 - (a) if the seed is cannabis seed harvested from an industrial cannabis plant—the package containing the seed has a label on it or attached to it that describes the contents of the package as cannabis seed harvested from an industrial cannabis plant; or

SCHEDULE 8 (continued)

- (b) if the seed is certified cannabis seed—the package containing the seed has a label on it, or attached to it, that describes the contents of the package as certified cannabis seed.
- 11.** A category 2 researcher must ensure, as far as practicable, that cannabis seed supplied to the researcher by a person in another State or a foreign country is certified as seed that, if grown, will produce cannabis plants with a THC concentration in their leaves and flowering heads of less than 3%.
 - 12.** A grower must ensure, as far as practicable, that cannabis seed supplied to the grower by a person in another State or a foreign country is certified as seed that, if grown, will produce cannabis plants with a THC concentration in their leaves and flowering heads of not more than 0.5%.

SCHEDULE 9**DICTIONARY**

section 2

“analyst” means a person who holds an approval under the *Health (Drugs and Poisons) Regulation 1996* to obtain, possess and use standard THC material to calibrate an analytical instrument used for analysing a substance to determine its THC concentration.

“carrier” means a person who carries on a business of transporting a thing for delivery to the person to whom it is consigned, whether in Queensland or elsewhere, and whether the thing is transported by air, rail, road or sea.

“consigned” includes addressed.

“consigned cannabis” means any of the following—

- (a) industrial cannabis plants;
- (b) industrial cannabis seed;
- (c) class A research cannabis;
- (d) class B research cannabis;
- (e) processed cannabis.

“DPI researcher” means a public service officer—

- (a) who is employed in the department within which the *Agricultural Standards Act 1994* is administered; and
- (b) whose duties include plant breeding; and
- (c) who is authorised by the chief executive in writing to perform activities stated in part 4, division 4.

“seed supplier” means a person recognised as a seed supplier under section 27.

“standard THC material” means THC of a known purity.

SCHEDULE 9 (continued)

“supply”—

- (a) for part 3, see section 43A⁹ of the Act; or
- (b) for part 4, does not include administer.

ENDNOTES

1 Index to endnotes

	Page
2 Date to which amendments incorporated	47
3 Key	47
4 Table of earlier reprints	48
5 List of legislation	48
6 List of annotations	50

2 Date to which amendments incorporated

This is the reprint date mentioned in the Reprints Act 1992, section 5(c). Accordingly, this reprint includes all amendments that commenced operation on or before 20 December 2002. Future amendments of the Drugs Misuse Regulation 1987 may be made in accordance with this reprint under the Reprints Act 1992, section 49.

3 Key

Key to abbreviations in list of legislation and annotations

Key	Explanation	Key	Explanation
AIA	= Acts Interpretation Act 1954	(prev)	= previously
amd	= amended	proc	= proclamation
amdt	= amendment	prov	= provision
ch	= chapter	pt	= part
def	= definition	pubd	= published
div	= division	R[X]	= Reprint No.[X]
exp	= expires/expired	RA	= Reprints Act 1992
gaz	= gazette	reloc	= relocated
hdg	= heading	renum	= renumbered
ins	= inserted	rep	= repealed
lap	= lapsed	(retro)	= retrospectively
notfd	= notified	s	= section
o in c	= order in council	sch	= schedule
om	= omitted	sdiv	= subdivision
orig	= original	SIA	= Statutory Instruments Act 1992
p	= page	SIR	= Statutory Instruments Regulation 2002
para	= paragraph	SL	= subordinate legislation
prec	= preceding	sub	= substituted
pres	= present	unnum	= unnumbered
prev	= previous		

4 Table of earlier reprints

Reprints are issued for both future and past effective dates. For the most up-to-date table of earlier reprints, see the latest reprint.

If a reprint number includes a letter of the alphabet, the reprint was released in unauthorised, electronic form only.

TABLE OF EARLIER REPRINTS

Reprint No.	Amendments included	Effective	Reprint date
1	to reg pubd gaz 6 May 1989	6 May 1989	23 April 1993
2	to SL No. 309 of 1996	8 November 1996	4 December 1996
2A	to SL No. 303 of 1997	19 September 1997	21 November 1997
2B	to SL No. 459 of 1997	19 December 1997	14 August 1998
3	to SL No. 348 of 1998	18 December 1998	5 February 1999
3A	to SL No. 41 of 1999	26 March 1999	8 April 1999
3B	to SL No. 235 of 1999	22 October 1999	2 December 1999
3C	to Act No. 28 of 2000	27 July 2000	11 August 2000
3D	to SL No. 234 of 2000	8 September 2000	15 September 2000
3E	to SL No. 52 of 2001	25 May 2001	8 June 2001
4	to SL No. 174 of 2001	21 September 2001	5 October 2001
4A	to SL No. 249 of 2001	7 December 2001	14 December 2001
4B	to SL No. 255 of 2002	27 September 2002	

5 List of legislation

Drugs Misuse Regulation 1987

made by the Administrator of the Government on 29 October 1987
 pubd gaz 31 October 1987 pp 836–47
 commenced 31 October 1987 (see s 2)
 exempted from application of SIA pt 7 (see SIA sch 2A)

Note—This regulation contains provisions relocated from the Drugs Misuse Act 1986. A list of legislation for the relocated provisions of the Drugs Misuse Act 1986 appears below.

as amended by—

regulations published gazette (pre SL series)—

17 December 1988 pp 2214–5
 commenced on date of publication

6 May 1989 pp 230–1
 commenced 6 May 1989 (see s 2)

Drugs Misuse Amendment Regulation (No. 1) 1996 SL No. 309

notfd gaz 8 November 1996 pp 959–61
 ss 1–2 commenced on date of notification
 remaining provisions commenced 8 November 1996 (see s 2)

**List of legislation to Drugs Misuse Act 1986 No. 36 schs 1–6—before relocation to
Drugs Misuse Regulation 1987 as schs 1–6 (see 1996 No. 49 s 21)—****Original relocated Act****Drugs Misuse Act 1986 No. 36 schs 1–6**

date of assent 5 September 1986

ss 1–2 commenced on date of assent

remaining provisions commenced 27 October 1986 (proc pubd gaz 25 October 1986
p 1242)

as amended by—

Drugs Misuse Act Amendment Act 1987 No. 53

date of assent 1 October 1987

ss 1–2 commenced on date of assent

s 10(a)(iii) commenced 6 May 1989 (proc pubd gaz 6 May 1989 p 213)

remaining provisions commenced 31 October 1987 (proc pubd gaz 31 October 1987
p 819)**Drugs Misuse Act Amendment Act 1989 No. 34**

date of assent 28 April 1989

ss 1–2 commenced on date of assent

remaining provisions commenced 6 May 1989 (proc pubd gaz 6 May 1989 p 213)

Statute Law (Miscellaneous Provisions) Act 1990 No. 88 s 3 sch

date of assent 6 December 1990

commenced on date of assent

Drugs Misuse Amendment Act 1995 No. 18

date of assent 11 April 1995

ss 1–2 commenced on date of assent

s 6 commenced 8 December 1995 (1995 SL No. 358)

remaining provisions commenced 12 April 1996 (automatic commencement under
AIA s 15DA(2))**Drugs Misuse Amendment Act 1996 No. 49**

date of assent 15 November 1996

commenced on date of assent

**List of legislation to Drugs Misuse Regulation 1987—after relocation of Drugs
Misuse Act 1986 No. 36 schs 1–6****Drugs Misuse Amendment Regulation (No. 1) 1997 SL No. 303**

notfd gaz 19 September 1997 pp 262–3

commenced on date of notification

Drugs Misuse Amendment Regulation (No. 2) 1997 SL No. 459

notfd gaz 19 December 1997 pp 1770–77

commenced on date of notification

Drugs Misuse Amendment Regulation (No. 1) 1998 SL No. 348

notfd gaz 18 December 1998 pp 1551–7

commenced on date of notification

Drugs Misuse Amendment Regulation (No. 1) 1999 SL No. 41

notfd gaz 26 March 1999 pp 1450–3
commenced on date of notification

Drugs Misuse Amendment Regulation (No. 2) 1999 SL No. 235

notfd gaz 22 October 1999 pp 710–1
commenced on date of notification

Drugs Misuse Amendment Act 2000 No. 28 pt 1 s 26 sch

date of assent 27 July 2000
commenced on date of assent

Drugs Misuse Amendment Regulation (No. 1) 2000 SL No. 234

notfd gaz 8 September 2000 pp 134–5
commenced on date of notification

Drugs Misuse Amendment Regulation (No. 1) 2001 SL No. 52

notfd gaz 25 May 2001 pp 334–6
commenced on date of notification

Drugs Misuse Amendment Regulation (No. 2) 2001 SL No. 174

notfd gaz 21 September 2001 pp 230–31
commenced on date of notification

Drugs Misuse Amendment Regulation (No. 3) 2001 SL No. 249

notfd gaz 7 December 2001 pp 1270–1
commenced on date of notification

Drugs Misuse Amendment Regulation (No. 1) 2002 SL No. 255

notfd gaz 27 September 2002 pp 340–4
commenced on date of notification

Drugs Misuse Amendment Regulation (No. 2) 2002 SL No. 368

notfd gaz 20 December 2002 pp 1359–63
commenced on date of notification

6 List of annotations

PART 1—PRELIMINARY

pt hdg ins 1996 SL No. 309 s 4

Dictionary

prov hdg pres s 2 hdg sub 1996 SL No. 309 s 5(1)

s 2 prev s 2 om R2 (see RA s 37)

pres s 2 (prev s 4) sub 1998 SL No. 348 s 3(2)

renum 2002 No. 255 s 3

def “**occupier’s notice**” reloc to sch 9 1998 SL No. 348 s 3(1)

def “**record of proceedings**” reloc to sch 9 1998 SL No. 348 s 3(1)

def “**search warrant**” reloc to sch 9 1998 SL No. 348 s 3(1)

def “**supply**” ins 1996 SL No. 309 s 5(3)

om 1998 SL No. 348 s 3(2)

def “**the Act**” sub 1989 reg pubd gaz 6 May 1989 pp 230–1
om 1996 SL No. 309 s 5(2)

PART 2—SYRINGES AND DANGEROUS DRUGS DISPOSAL PROCEDURES

pt hdg prev pt 2 hdg ins 1996 SL No. 309 s 6
om 2002 SL No. 255 s 4
pres pt 2 hdg (prev pt 3 hdg) ins 1996 SL No. 309 s 11
renum 2002 SL No. 255 s 5(1)

Prescribed procedures for the disposal of hypodermic syringes and needles

s 3 prev s 3 om R1 (see RA s 40)
pres s 3 (prev s 9) ins reg pubd gaz 6 May 1989 pp 230–1
renum 2002 SL No. 255 s 5(2)

Prescribed procedure for disposal of dangerous drugs

s 4 (prev s 10) ins reg pubd gaz 6 May 1989 pp 230–1
renum 2002 SL No. 255 s 5(2)

PART 3—CONTROLLED SUBSTANCES

pt hdg (prev pt 4 hdg) ins 1996 SL No. 309 s 12
renum 2002 SL No. 255 s 5(1)

Other act that is a relevant transaction—Act, s 43C(b)

s 5 prev s 5 amd 1996 SL No. 309 s 7
om 2002 SL No. 255 s 4
pres s 5 (prev s 11) ins 1996 SL No. 309 s 12
renum 2002 SL No. 255 s 5(2)

**Documents and proof of identity required for supply of a controlled substance—Act,
s 43D(1)(a)**

s 6 prev s 6 amd 1996 SL No. 309 s 8
om 2002 SL No. 255 s 4
pres s 6 (prev s 12) ins 1996 SL No. 309 s 12
renum 2002 SL No. 255 s 5(2)

Details about supply of controlled substance to be recorded in register

s 7 prev s 7 sub reg pubd gaz 17 December 1988 pp 2214–15
amd 1996 SL No. 309 s 9
om 2002 SL No. 255 s 4
pres s 7 (prev s 13) ins 1996 SL No. 309 s 12
renum 2002 SL No. 255 s 5(2)

Details about loss or theft of controlled substance to be recorded in register

s 8 prev s 8 om 1996 SL No. 309 s 10
pres s 8 (prev s 14) ins 1996 SL No. 309 s 12
renum 2002 SL No. 255 s 5(2)

Keeping of register, invoice and other documents

s 9 (prev s 15) ins 1996 SL No. 309 s 12
renum 2002 SL No. 255 s 5(2)

PART 4—COMMERCIAL PRODUCTION OF INDUSTRIAL CANNABIS

pt hdg (prev pt 5 hdg) ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Division 1—Preliminary

div hdg ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Operation of pt 4 and schs 7 and 8

s 10 ins 2002 SL No. 255 s 6

Division 2—Certified cannabis seed

div hdg ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Certifying cannabis seed

s 11 ins 2002 SL No. 255 s 6

Division 3—Carriers

div hdg ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Application of div 3

s 12 ins 2002 SL No. 255 s 6

Supply

s 13 ins 2002 SL No. 255 s 6

Possession

s 14 ins 2002 SL No. 255 s 6

Division 4—DPI researchers

div hdg ins 2002 SL No. 255 s 6

Supply

s 15 ins 2002 SL No. 255 s 6

Production

s 16 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Possession

s 17 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Division 5—Inspectors

div hdg ins 2002 SL No. 255 s 6

Supply

s 18 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Possession

s 19 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Division 6—Seed suppliers

div hdg ins 2002 SL No. 255 s 6

Supply

s 20 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Possession

s 21 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Division 7—Other persons

div hdg ins 2002 SL No. 255 s 6

Denaturer

s 22 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Manufacturer

s 23 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Analyst

s 24 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Family members

s 25 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Employees of authorised persons

s 26 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Division 8—Other provisions

div hdg ins 2002 SL No. 255 s 6

Recognition as seed supplier

s 27 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Licence fees

s 28 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Licence conditions, Act, s 64

s 29 ins 2001 SL No. 52 s 3
sub 2002 SL No. 255 s 6

PART 5—TRANSITIONAL PROVISIONS

pt hdg (prev pt 6 hdg) ins 2001 SL No. 174 s 3
renum 2002 SL No. 255 s 5(1)
amd 2002 SL No. 368 s 3

Transitional provision for Drugs Misuse Amendment Regulation (No. 2) 2001

s 30 ins 2001 SL No. 174 s 3

Transitional provision for Drugs Misuse Amendment Regulation (No. 2) 2002

s 31 ins 2002 SL No. 368 s 4

SCHEDULE

amd reg pubd gaz 17 December 1988 pp 2214–5
om 1996 SL No. 309 s 13

SCHEDULE 1—DANGEROUS DRUGS

sch hdg ins 1997 SL No. 459 s 3(1)
(prev 1986 No. 36 sch 1)
amd 1996 No. 49 s 15
reloc 1996 No. 49 s 21
amd 1997 SL No. 459 s 3(2); 2001 SL No. 174 s 4; 2002 SL No. 255 s 7(1)

SCHEDULE 2—DANGEROUS DRUGS

sch hdg ins 1997 SL No. 459 s 4(1)
(prev 1986 No. 36 sch 2)
amd 1987 No. 53 s 11; 1989 No. 34 s 22; 1996 No. 49 s 16
reloc 1996 No. 49 s 21
amd 1997 SL No. 303 s 3; 1997 SL No. 459 s 4(2)–(3); 1999 SL No. 41 s 3;
2001 SL No. 174 s 5; 2001 SL No. 249 s 3; 2002 SL No. 255 s 7(1); 2002
SL No. 368 s 5

SCHEDULE 2A—DANGEROUS DRUGS

ins 2000 No. 28 s 26 sch
amd 2002 SL No. 255 s 7(1); 2002 SL No. 368 s 6

SCHEDULE 3—SPECIFIED QUANTITIES FOR PARTICULAR DANGEROUS DRUGS

sch hdg ins 1997 SL No. 459 s 5(1)
(prev 1986 No. 36 sch 3)
amd 1987 No. 53 s 12; 1989 No. 34 s 23
sub 1990 No. 88 s 3 sch
amd 1996 No. 49 s 17
reloc 1996 No. 49 s 21
amd 1997 SL No. 303 s 4; 1997 SL No. 459 s 5(2)–(3); 1999 SL No. 41 s 4;
2001 SL No. 249 s 4; 2002 SL No. 255 s 7(1)–(2); 2002 SL No. 368 s 7

SCHEDULE 4—SPECIFIED QUANTITIES FOR PARTICULAR DANGEROUS DRUGS

sch hdg ins 1997 SL No. 459 s 6(1)
(prev 1986 No. 36 sch 4)
amd 1996 No. 49 s 18
reloc 1996 No. 49 s 21
amd 1997 SL No. 459 s 6(2); 2001 SL No. 174 s 6; 2002 SL No. 255 s 7(1)

SCHEDULE 5—DANGEROUS DRUGS

sch hdg ins 1997 SL No. 459 s 7(1)
(prev 1986 No. 36 sch 5)
amd 1987 No. 53 s 13; 1996 No. 49 s 19
reloc 1996 No. 49 s 21
amd 1997 SL No. 459 s 7(2); 2002 SL No. 255 s 7(1), (3)

SCHEDULE 6—CONTROLLED SUBSTANCES

(prev 1986 No. 36 sch 6)
 prev sch 6 om R1 (see RA s 40)
 pres sch 6 ins 1995 No. 18 s 8
 amd 1996 No. 49 s 20
 reloc 1996 No. 49 s 21
 amd 1997 SL No. 459 s 8; 2002 SL No. 255 s 7(1)

**SCHEDULE 7—CONDITIONS FOR PARTICULAR PERSONS AUTHORISED
UNDER PART 4**

sch hdg ins 1998 SL No. 348 s 5
 sub 2002 SL No. 255 s 8

Denaturer

s 1 ins 1998 SL No. 348 s 5
 sub 2002 SL No. 255 s 8

DPI researcher

s 2 ins 1998 SL No. 348 s 5
 sub 2002 SL No. 255 s 8

Inspector

s 3 ins 1998 SL No. 348 s 5
 sub 2002 SL No. 255 s 8

Seed supplier

s 4 ins 1998 SL No. 348 s 5
 amd 1999 SL No. 235 s 3
 sub 2002 SL No. 255 s 8

Analyst

s 5 ins 2002 SL No. 255 s 8

SCHEDULE 8—LICENCE CONDITIONS

ins 1998 SL No. 348 s 5
 sub 1999 SL No. 235 s 4; 2000 SL No. 234 s 3; 2002 SL No. 255 s 8

SCHEDULE 9—DICTIONARY

ins 1998 SL No. 348 s 5
 sub 2002 SL No. 255 s 8
 def “**occupier’s notice**” reloc 1998 SL No. 348 s 3(1)
 om 2002 SL No. 255 s 8
 def “**record of proceedings**” reloc 1998 SL No. 348 s 3(1)
 om 2002 SL No. 255 s 8
 def “**search warrant**” reloc 1998 SL No. 348 s 3(1)
 om 2002 SL No. 255 s 8